ATRA News and Press, Atara Biotherapeutics Inc.

2026-02-25 13:56:52 ET More on Atara Biotherapeutics Atara Biotherapeutics: An Empty Pipeline With Little Gas Atara plummets on FDA Complete Response Letter for tabelecleucel Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings dat...

Atara renegotiates one-time milestone payment with HCRx Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmun...

2026-01-13 14:05:09 ET from New Street issued a price target of $6.00 for ATRA on 2026-01-13 18:37:08. The adjusted price target was set to $6.00. At the time of the announcement, ATRA was trading at $4.42. The overall price target consensus is at $25.00 with high price ...

A look at the top 10 most actives in the United States Envirotech Vehicles Inc. (EVTV) rose 442.0% to $2.51 on volume of 760,991,766 shares Oriental Culture Holding LTD (OCG) fell 15.5% to $0.0169 on volume of 452,241,771 shares Mingteng International Corporation Inc. (MTEN) fell 41.9% to $...

A look at the top 10 most actives in the United States Envirotech Vehicles Inc. (EVTV) rose 295.2% to $1.83 on volume of 610,320,780 shares Oriental Culture Holding LTD (OCG) fell 15.0% to $0.017 on volume of 389,655,949 shares Mingteng International Corporation Inc. (MTEN) fell 43.7% to $0...

2026-01-12 12:42:49 ET More on Atara Biotherapeutics Atara Biotherapeutics: An Empty Pipeline With Little Gas Atara Biotherapeutics GAAP EPS of -$0.32 beats by $0.37, revenue of $3.5M beats by $0.76M Seeking Alpha’s Quant Rating on Atara Biotherapeutics ...

U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with ...

2025-11-30 08:51:44 ET Topline Summary Read the full article on Seeking Alpha For further details see: Atara Biotherapeutics: An Empty Pipeline With Little Gas

2025-11-12 10:37:03 ET More on Atara Biotherapeutics Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics Financial information for Atara Biotherapeutics Read the full article on Seeking Alpha ...

Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre Fabre Laboratories Approval of BLA would unlock a $40 Million m...